Fig. 4: Fc-fusion and antigen dosage contribute to the unadjuvanted mucosal immunogenicity of 4RBD-Fc. | Communications Biology

Fig. 4: Fc-fusion and antigen dosage contribute to the unadjuvanted mucosal immunogenicity of 4RBD-Fc.

From: Single-dose infusion of engineered viral receptor binding domain confers rapid and durable protection against viral infection

Fig. 4

A Experimental design evaluating whether dosage or structure affects the mucosal immunogenicity of unadjuvanted 4RBD-Fc (n = 4). B Serum anti-RBD IgG antibodies titers among different antigen and dosage treatment, measured by ELISA. The dashed line indicates the limit of detection (LOD). Undetectable values were set to LOD – 0.2 log units to distinguish them. Quantitative analyses of RBD-specific B cell responses in mdLN, including numbers (C) and percentages (D) of RBD+ B cells, as well as their differentiation status (E). The percentage of pulmonary T cells responsive to RBD peptide library stimulation, including CD4+ (F) and CD8+ T cells (G). H DC subsets in mdLN following i.n. administration of indicated antigen: cDC (MHC-II+CD11chi), iDC (MHC-II+CD11clo), tDC (MHC-IIhiCD11c+). Data are presented as mean ± s.d. Symbols indicate data collected from individual mice. Statistical significance was calculated by one-way ANOVA with Dunnett correction.

Back to article page